Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).
D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003857:Deoxyuridine / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D013936:Thymidine / Q000627:therapeutic use* / Q000633:toxicity; D013997:Time Factors
D005467:Floxuridine; D013936:Thymidine; D003857:Deoxyuridine